Triazolyl tryptoline derivatives as β-secretase inhibitors

Abstract

Tryptoline, a core structure of ochrolifuanine E, which is a hit compound from virtual screening of the Thai herbal database against BACE1 was used as a scaffold for the design of BACE1 inhibitors. The tryptoline was linked with different side chains by 1,2,3-triazole ring readily synthesized by catalytic azide-alkyne cycloaddition reactions. Twenty two triazolyl tryptoline derivatives were synthesized and screened for the inhibitory action against BACE1. JJCA-140 was the most potent inhibitor (IC₅₀ = 1.49 μM) and was 100 times more selective for BACE1 than for Cat-D.

Original language	English
Pages (from-to)	6572-6576
Number of pages	5
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	20
Issue number	22
DOIs	https://doi.org/10.1016/j.bmcl.2010.09.043
Publication status	Published - 15 Nov 2010
Externally published	Yes

Keywords

BACE1
BACE1 inhibitor
Binding mode
Cathepsin-D
Docking
Enzyme assay
JJCA-140
Tryptoline

ASJC Scopus subject areas

Pharmaceutical Science
Drug Discovery
Organic Chemistry
Molecular Medicine
Molecular Biology
Clinical Biochemistry
Biochemistry

Access to Document

10.1016/j.bmcl.2010.09.043

Fingerprint Dive into the research topics of 'Triazolyl tryptoline derivatives as β-secretase inhibitors'. Together they form a unique fingerprint.

Cite this

@article{a0171cb15d594549b78863b7bd5f9c4b,

title = "Triazolyl tryptoline derivatives as β-secretase inhibitors",

abstract = "Tryptoline, a core structure of ochrolifuanine E, which is a hit compound from virtual screening of the Thai herbal database against BACE1 was used as a scaffold for the design of BACE1 inhibitors. The tryptoline was linked with different side chains by 1,2,3-triazole ring readily synthesized by catalytic azide-alkyne cycloaddition reactions. Twenty two triazolyl tryptoline derivatives were synthesized and screened for the inhibitory action against BACE1. JJCA-140 was the most potent inhibitor (IC50 = 1.49 μM) and was 100 times more selective for BACE1 than for Cat-D.",

keywords = "BACE1, BACE1 inhibitor, Binding mode, Cathepsin-D, Docking, Enzyme assay, JJCA-140, Tryptoline",

author = "Jutamas Jiaranaikulwanitch and Chantana Boonyarat and Fokin, {Valery V.} and Opa Vajragupta",

year = "2010",

month = nov,

day = "15",

doi = "10.1016/j.bmcl.2010.09.043",

language = "English",

volume = "20",

pages = "6572--6576",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "22",

}

TY - JOUR

T1 - Triazolyl tryptoline derivatives as β-secretase inhibitors

AU - Jiaranaikulwanitch, Jutamas

AU - Boonyarat, Chantana

AU - Fokin, Valery V.

AU - Vajragupta, Opa

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Tryptoline, a core structure of ochrolifuanine E, which is a hit compound from virtual screening of the Thai herbal database against BACE1 was used as a scaffold for the design of BACE1 inhibitors. The tryptoline was linked with different side chains by 1,2,3-triazole ring readily synthesized by catalytic azide-alkyne cycloaddition reactions. Twenty two triazolyl tryptoline derivatives were synthesized and screened for the inhibitory action against BACE1. JJCA-140 was the most potent inhibitor (IC50 = 1.49 μM) and was 100 times more selective for BACE1 than for Cat-D.

AB - Tryptoline, a core structure of ochrolifuanine E, which is a hit compound from virtual screening of the Thai herbal database against BACE1 was used as a scaffold for the design of BACE1 inhibitors. The tryptoline was linked with different side chains by 1,2,3-triazole ring readily synthesized by catalytic azide-alkyne cycloaddition reactions. Twenty two triazolyl tryptoline derivatives were synthesized and screened for the inhibitory action against BACE1. JJCA-140 was the most potent inhibitor (IC50 = 1.49 μM) and was 100 times more selective for BACE1 than for Cat-D.

KW - BACE1

KW - BACE1 inhibitor

KW - Binding mode

KW - Cathepsin-D

KW - Docking

KW - Enzyme assay

KW - JJCA-140

KW - Tryptoline

UR - http://www.scopus.com/inward/record.url?scp=77958063689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958063689&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2010.09.043

DO - 10.1016/j.bmcl.2010.09.043

M3 - Article

C2 - 20943389

AN - SCOPUS:77958063689

VL - 20

SP - 6572

EP - 6576

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 22